Prelude Therapeutics Inc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Prelude Therapeutics Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Prelude Therapeutics Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$32.3M, a 5.43% decline year-over-year.
  • Prelude Therapeutics Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$132M, a 12% decline year-over-year.
  • Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$122M, a 5.54% decline from 2022.
  • Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$115M, a 3.35% decline from 2021.
  • Prelude Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$112M, a 96.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$132M -$32.3M -$1.66M -5.43% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$130M -$34.7M -$4.31M -14.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$126M -$31.4M -$3.71M -13.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$122M -$33.1M -$4.43M -15.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$117M -$30.6M -$650K -2.17% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$117M -$30.4M -$3.06M -11.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$114M -$27.7M +$1.75M +5.93% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$115M -$28.6M +$4.2M +12.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$120M -$30M +$729K +2.38% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$120M -$27.4M -$509K -1.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$120M -$29.5M -$8.17M -38.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$112M -$32.8M -$13.6M -70.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$98.1M -$30.7M -$13.9M -83.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$84.2M -$26.9M -$15.5M -135% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$68.7M -$21.3M -$11.8M -124% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$56.9M -$19.3M -$9.21M -91.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$47.7M -$16.8M -$10M -149% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$37.7M -$11.4M -$5.85M -105% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$31.8M -$9.51M -$4.27M -81.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$27.6M -$10M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 -$6.73M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$5.56M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$5.24M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.